HER2-overexpressing/amplified breast cancer as a testing ground for antibody-drug conjugate drug development in solid tumors
2019
Efficacy data from the KATHERINE clinical trial comparing ado-trastuzumab emtansine (T-DM1) to trastuzumab in patients with early-stage human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer with residual disease after neoadjuvant therapy (hazard ratio for invasive disease or death, 0.50; P
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
79
References
15
Citations
NaN
KQI